MA41653A - Liants de tnf améliorés - Google Patents

Liants de tnf améliorés

Info

Publication number
MA41653A
MA41653A MA041653A MA41653A MA41653A MA 41653 A MA41653 A MA 41653A MA 041653 A MA041653 A MA 041653A MA 41653 A MA41653 A MA 41653A MA 41653 A MA41653 A MA 41653A
Authority
MA
Morocco
Prior art keywords
enhanced tnf
tnf binders
binders
enhanced
tnf
Prior art date
Application number
MA041653A
Other languages
English (en)
French (fr)
Inventor
Joachim Boucneau
Marie-Ange Buyse
Peter Casteels
Heeke Gino Van
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MA41653A publication Critical patent/MA41653A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Organic Insulating Materials (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
MA041653A 2015-11-12 2016-11-13 Liants de tnf améliorés MA41653A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562254375P 2015-11-12 2015-11-12

Publications (1)

Publication Number Publication Date
MA41653A true MA41653A (fr) 2018-01-09

Family

ID=57348648

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041653A MA41653A (fr) 2015-11-12 2016-11-13 Liants de tnf améliorés

Country Status (37)

Country Link
US (2) US10544211B2 (index.php)
EP (2) EP3191511B1 (index.php)
JP (2) JP6962915B2 (index.php)
KR (2) KR20240029115A (index.php)
CN (1) CN108473563B (index.php)
AU (2) AU2016352943B2 (index.php)
BR (1) BR112018009714A8 (index.php)
CA (2) CA3005085C (index.php)
CL (1) CL2018001291A1 (index.php)
CO (1) CO2018005915A2 (index.php)
CR (1) CR20180311A (index.php)
CY (1) CY1120303T1 (index.php)
DK (1) DK3191511T3 (index.php)
DO (1) DOP2018000122A (index.php)
EC (1) ECSP18042569A (index.php)
ES (1) ES2662418T3 (index.php)
GT (1) GT201800095A (index.php)
HK (1) HK1248716A1 (index.php)
HR (1) HRP20171949T1 (index.php)
HU (1) HUE035805T2 (index.php)
IL (2) IL259269B2 (index.php)
LT (1) LT3191511T (index.php)
MA (1) MA41653A (index.php)
MD (1) MD3191511T2 (index.php)
ME (1) ME02954B (index.php)
MX (1) MX385207B (index.php)
NO (1) NO2768984T3 (index.php)
PE (1) PE20181317A1 (index.php)
PH (1) PH12018501025A1 (index.php)
PL (1) PL3191511T3 (index.php)
PT (1) PT3191511T (index.php)
RS (1) RS56676B1 (index.php)
SG (1) SG11201803975SA (index.php)
SI (1) SI3191511T1 (index.php)
SM (1) SMT201700590T1 (index.php)
TN (1) TN2018000159A1 (index.php)
WO (1) WO2017081320A1 (index.php)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PH12013502669B1 (en) 2011-06-23 2018-08-10 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
RU2746738C2 (ru) 2014-05-16 2021-04-20 Аблинкс Нв Улучшенные вариабельные домены иммуноглобулина
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
NO2768984T3 (index.php) * 2015-11-12 2018-06-09
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
JP7719775B2 (ja) 2019-12-06 2025-08-06 アブリンクス エン．ヴェー． ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
IL293561A (en) 2019-12-06 2022-08-01 Ablynx Nv Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23
CN112300289B (zh) * 2019-12-30 2022-06-10 中国药科大学 RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用
US11897951B2 (en) * 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
US20250026842A1 (en) * 2021-11-29 2025-01-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Modified protein or polypeptide
AU2023373192A1 (en) * 2022-11-04 2025-04-17 St. Jude Children's Research Hospital, Inc. Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
US20240415974A1 (en) 2022-12-23 2024-12-19 Ablynx N.V. Protein-based conjugation carriers
AU2024221136A1 (en) 2023-02-17 2025-10-02 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU2152299A (en) 1997-10-27 1999-05-24 Unilever Plc Multivalent antigen-binding proteins
US20020155604A1 (en) 1998-02-19 2002-10-24 Jeffrey A. Ledbetter Compositions and methods for regulating lymphocyte activation
WO2004081026A2 (en) 2003-06-30 2004-09-23 Domantis Limited Polypeptides
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP2284192A3 (en) * 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
MXPA05006043A (es) 2003-01-10 2006-01-30 Ablynx Nv Polipeptidos terapeuticos, homologos de los mismos, fragmentos de los mismos y para uso al modular la agregacion mediada de plaquetas.
AU2003283136A1 (en) 2003-11-07 2005-05-26 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
KR20070084170A (ko) 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
EP1863847A2 (en) 2004-12-02 2007-12-12 Domantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
LT2949668T (lt) * 2005-05-18 2019-11-11 Ablynx Nv Pagerinti nanokūnai tm prieš navikų nekrozės faktorių alfa
TR201815552T4 (tr) 2005-05-20 2018-11-21 Ablynx Nv Agregasyon ile ilgili hastalıkların tedavisine yönelik iyileştirilmiş nanoantikorlar (TM).
DE102005023617A1 (de) * 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
WO2007025977A2 (en) 2005-08-30 2007-03-08 Actogenix Nv Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
CA2629850A1 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
EP1957536A2 (en) 2005-12-01 2008-08-20 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
EP2441838A3 (en) 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
AU2007328900A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
WO2008142164A2 (en) 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
JP2011504740A (ja) 2007-11-27 2011-02-17 アブリンクス エン．ヴェー． ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
AU2009248049B2 (en) 2008-05-16 2015-07-23 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
WO2010094720A2 (en) * 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists
JP5647222B2 (ja) 2009-04-10 2014-12-24 アブリンクス エン．ヴェー． Ｉｌ−６ｒ関連疾患及び障害の治療のためのｉｌ−６ｒに指向性を有する改善されたアミノ酸配列及びこれを含むポリペプチド
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
EA201270174A1 (ru) 2009-07-16 2012-07-30 Глэксо Груп Лимитед Отдельные связывающиеся вариабельные домены с улучшенными свойствами, направленные против сывороточного альбумина
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
AU2012234284B2 (en) 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
AU2012271974B2 (en) 2011-06-23 2017-01-12 Ablynx Nv Serum albumin binding proteins
PH12013502669B1 (en) * 2011-06-23 2018-08-10 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MX2014001883A (es) * 2011-08-17 2014-05-27 Glaxo Group Ltd Proteinas y peptidos modificados.
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
RU2746738C2 (ru) * 2014-05-16 2021-04-20 Аблинкс Нв Улучшенные вариабельные домены иммуноглобулина
NO2768984T3 (index.php) * 2015-11-12 2018-06-09
JP7540877B2 (ja) * 2016-02-12 2024-08-27 アブリンクス エン．ヴェー． 免疫グロブリン単一可変ドメインの生成方法

Also Published As

Publication number Publication date
CY1120303T1 (el) 2019-07-10
PE20181317A1 (es) 2018-08-14
AU2023200113A1 (en) 2023-02-16
EP3191511A1 (en) 2017-07-19
MX385207B (es) 2025-03-04
ES2662418T3 (es) 2018-04-06
US20170267752A1 (en) 2017-09-21
CR20180311A (es) 2018-10-18
JP6962915B2 (ja) 2021-11-10
US9745372B2 (en) 2017-08-29
PL3191511T3 (pl) 2018-03-30
EP3266798A3 (en) 2018-03-28
CL2018001291A1 (es) 2018-09-14
DK3191511T3 (en) 2018-01-08
SMT201700590T1 (it) 2018-01-11
GT201800095A (es) 2019-08-15
PH12018501025A1 (en) 2019-01-28
JP2022020666A (ja) 2022-02-01
AU2016352943A1 (en) 2018-06-07
CN108473563B (zh) 2022-06-14
IL259269B2 (en) 2024-07-01
EP3191511B1 (en) 2017-09-20
IL259269B1 (en) 2024-03-01
CO2018005915A2 (es) 2018-06-20
CA3005085C (en) 2024-09-10
LT3191511T (lt) 2018-01-10
RS56676B1 (sr) 2018-03-30
US20170190769A1 (en) 2017-07-06
RU2018120524A3 (index.php) 2020-09-24
JP2019506839A (ja) 2019-03-14
US10544211B2 (en) 2020-01-28
EP3266798A2 (en) 2018-01-10
MX2018005992A (es) 2019-01-31
BR112018009714A8 (pt) 2019-02-26
CN108473563A (zh) 2018-08-31
IL259269A (en) 2018-07-31
IL310373A (en) 2024-03-01
AU2016352943B2 (en) 2022-10-20
SI3191511T1 (en) 2018-01-31
WO2017081320A1 (en) 2017-05-18
KR102641194B1 (ko) 2024-02-26
TN2018000159A1 (en) 2019-10-04
JP7357038B2 (ja) 2023-10-05
SG11201803975SA (en) 2018-06-28
CA3234178A1 (en) 2017-05-18
NO2768984T3 (index.php) 2018-06-09
KR20180083382A (ko) 2018-07-20
ECSP18042569A (es) 2018-07-31
HK1248716A1 (en) 2018-10-19
DOP2018000122A (es) 2018-09-30
MD3191511T2 (ro) 2018-03-31
BR112018009714A2 (en) 2018-11-21
CA3005085A1 (en) 2017-05-18
ME02954B (me) 2018-07-20
HUE035805T2 (en) 2018-05-28
RU2018120524A (ru) 2019-12-13
HRP20171949T1 (hr) 2018-01-26
KR20240029115A (ko) 2024-03-05
PT3191511T (pt) 2017-11-30

Similar Documents

Publication Publication Date Title
DK3411065T3 (da) Clec9a-bindingsmidler
MA43259A (fr) Liants ctla4
MA41653A (fr) Liants de tnf améliorés
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
EP3327220A4 (en) BINDING MACHINE
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
EP3316375A4 (en) Redox flow cell
DK3305788T3 (da) Janus-kinase-hæmmer
DK3360890T3 (da) Genterapi
DK3331529T3 (da) Muskarinagonister
EP3290364A4 (en) Conveyor belt wear monitoring system
DK3310450T3 (da) Olie-vand-separator
EP3327221A4 (en) BINDING MACHINE
DK3270930T3 (da) Præeklampsi
DK3394281T3 (da) Gærcelle
DK3292136T3 (da) Penicillin-g-acylaser
DE112015006486A5 (de) Inkubationsrinne
PL3122568T5 (pl) Książeczka zabezpieczona
EP3396460A4 (en) CLEANING BLADE
DK3274482T3 (da) Stenborsknop
DK3318308T3 (da) Badmintonketsjer
DE102015206660A8 (de) Plattenaufteilanlage
EP3396467A4 (en) CLEANING BLADE